Big pharma gets creative

With blockbuster drug patents set to expire in the next few years, big pharma is looking hard for ways to pack the discovery pipeline. One approach: the biotech model. Patrick Vallance, the head of drug discovery at GlaxoSmithKline, said at a meeting on Friday (June 6) that research at the company would be reorganized to be "more biotech-like," the Financial Times linkurl:reported.;http://www.ft.com/cms/s/0/a36193c0-366e-11dd-8bb8-0000779fd2ac.html?nclick_check=1 He said the plan was to split